HBV SEROCONVERSION ON PATIENTS TREATED WITH NUCLEOS(T)IDE ANALOGUE REVERSE TRANSCRIPTASE INHIBITORS IN YEAR 2015-2018 AT DR. SARDJITO GENERAL HOSPITAL, YOGYAKARTA

ABDUL AZIZ, Dr. dr. Neneng Ratnasari Sp.PD, K-GEH; dr. Catharina Triwikatmani Sp.PD, M.Kes

2020 | Skripsi | S1 KEDOKTERAN

Latar Belakang: Infeksi virus hepatitis B adalah penyakit virus yang bisa mengakibatkan berbagai penyakit hati seperti sirosis hepatis, karsinoma hepatoseluler atau asimptomatik carrier. Analog nukleos(t)ida diberikan kepada pasien dengan infeksi VHB kronis sebagai salah satu alternatif perawatan. Oleh karena itu, penelitian dibuat untuk menentukan kemampuan analog nukleos(t)ida sebagai terapi infeksi VHB kronis. Tujuan penelitian: Tujuan penelitian ini dijalankan adalah untuk memahami kemampuan analog nukleos(t)ida sebagai alternatif terapi infeksi VHB kronis dengan mengobservasi tingkat DNA VHB pada pasien dalam rentang waktu tertentu. Metode penelitian: Penelitian ini adalah penelitian observasional retrospektif kohort dimana rekam medis pasien akan diteliti. Sejumlah 51 orang pasien telah direkrut untuk penelitian ini dan tingkat DNA VHB mereka selama 3 tahun kebelakang diteliti. Data tersebut kemudian dihitung untuk mendapatkan rerata tingkat DNA VHB setiap rentang waktu 6 bulan. Setiap hasil terapi pasien dikelompokkan berdasarkan tingkat DNA VHB kemudian tes asosiasi dilakukan untuk mencari hubungan antara tingkat baseline DNA VHB dengan hasil terapi. Hasil penelitian: Ditemukan tingkat DNA VHB berkurang secara signifikan pada 6 bulan pertama penelitian. Selain itu, baseline DNA VHB tidak menunjukkan asosiasi dengan hasil terapi. Tidak ditemukan juga hubungan antara usia dan jenis kelamin dengan hasil perawatan. Kesimpulan: Nuklos(t)ida analog mampu dijadikan alternatif terapi infeksi VHB kronis karena terdapat pengurangan tingkat DNA VHB yang signifikan dalam 6 bulan

Background: Hepatitis B virus infection is a viral disease that infects the liver that may lead to progression to a wide range of liver diseases such as liver cirrhosis, hepatocellular carcinoma, or even asymptomatic carrier. Nucleos(t)ide analogue reverse transcriptase inhibitors are given to patients of chronic HBV infection as one of the treatment. Therefore, we will be conducting a study to detemine the efficacy of nucleos(t)ide analogue as the treatment of chronic hepatitis B virus infection. Research Objective: The objective of this study is to understand the efficacy of nucleoside analogue reverse transcriptase inhibitors as a treatment of chronic hepatitis B virus infection by observing the HBV DNA levels of the patients in a period of time. Method: This study is an observational retrospective cohort study in which the patients' medical record will be collected and reviewed. A total number of 51 patients were recruited in this study and their HBV DNA levels for the past 3 years are reviewed and obtained. The data is then calculated to obtain mean HBV DNA levels for each time period of 6 months. Each of the patients' treatment outcome are also grouped into categories based on HBV DNA levels. Furthermore, a test of association is done to figure out whether there is an association between baseline HBV DNA levels and treatment outcome. To carry out the test of association, the patients data are first grouped into each respective categories before testing. Result: It is found that HBV DNA levels has decrease significantly in the first 6 months of the study. Besides that, baseline HBV DNA levels of patients does not show an association with treatment outcome. Furthermore, there are also no association between age and gender with treatment outcome. Conclusion: Nucleos(t)ide analogue is efficacious as a treatment of chronic HBV infection as there are significant reduction in HBV DNA levels in 6 months.

Kata Kunci : Nucleos(t)ide analogue, hepatitis B, HBV DNA